.png){kind=icon}
.png){kind=icon}
Return
Half-dose neostigmine and low dose sugammadex as a reversal agent for vecuronium: a pilot randomized trial
.png){kind=icon}
PRE
AI
Z
L
D
Y
H
S
W
DOI：10.1016/j.accpm.2026.101865.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The incidence of residual neuromuscular blockade after surgery is still high, and the traditional neuromuscular blocking agent neostigmine has many disadvantages. Sugammadex represents a novel class of neuromuscular blocking antagonist, exhibiting selectivity for rocuronium and vecuronium. But the reversal effect of half-dose neostigmine combined with half-dose or low-dose Sugammadex for vecuronium is unknown. To explore better antagonistic options, we designed this clinical trial and compared it with a single antagonist.
Keywords:
neostigmine
sugammadex
vecuronium
neuromuscular blockade
reversal agent
Journal
A
IF:
4.7
Papers:
114
Citations:
0
Organization
Cited Papers